Emily Leproust Sells 18,880 Shares of Twist Bioscience (NASDAQ:TWST) Stock

Twist Bioscience Corporation (NASDAQ:TWST) CEO Emily Leproust sold 18,880 shares of the firm’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $95.00, for a total transaction of $1,793,600.00. Following the completion of the sale, the chief executive officer owned 824,039 shares in the company, valued at $78,283,705. The trade was a 2.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Twist Bioscience Stock Performance

TWST opened at $99.84 on Friday. The company has a current ratio of 2.70, a quick ratio of 2.42 and a debt-to-equity ratio of 0.03. The business’s 50 day moving average is $67.01 and its 200-day moving average is $51.44. The stock has a market cap of $6.22 billion, a PE ratio of -75.07 and a beta of 2.23. Twist Bioscience Corporation has a twelve month low of $23.30 and a twelve month high of $104.23.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Monday, May 4th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.22). Twist Bioscience had a negative return on equity of 26.73% and a negative net margin of 19.85%.The business had revenue of $110.72 million during the quarter, compared to the consensus estimate of $107.64 million. During the same period last year, the company earned ($0.66) earnings per share. The business’s quarterly revenue was up 19.3% compared to the same quarter last year. On average, analysts predict that Twist Bioscience Corporation will post -2.02 earnings per share for the current year.

Analyst Ratings Changes

TWST has been the topic of a number of research analyst reports. UBS Group set a $89.00 price target on Twist Bioscience in a report on Monday, June 15th. Barclays increased their target price on shares of Twist Bioscience from $65.00 to $95.00 and gave the company an “overweight” rating in a research report on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Twist Bioscience in a research note on Wednesday. Robert W. Baird boosted their price target on shares of Twist Bioscience from $50.00 to $65.00 and gave the stock an “outperform” rating in a research report on Tuesday, May 5th. Finally, TD Cowen upped their price target on shares of Twist Bioscience from $68.00 to $89.00 and gave the stock a “buy” rating in a research note on Monday, June 15th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Twist Bioscience currently has an average rating of “Moderate Buy” and an average target price of $74.60.

Institutional Investors Weigh In On Twist Bioscience

Several hedge funds and other institutional investors have recently bought and sold shares of the business. William Blair Investment Management LLC boosted its position in shares of Twist Bioscience by 43.7% during the 4th quarter. William Blair Investment Management LLC now owns 5,954,429 shares of the company’s stock valued at $188,874,000 after purchasing an additional 1,812,146 shares in the last quarter. EdgePoint Investment Group Inc. lifted its stake in Twist Bioscience by 71.1% during the third quarter. EdgePoint Investment Group Inc. now owns 4,082,319 shares of the company’s stock valued at $114,876,000 after purchasing an additional 1,696,377 shares during the last quarter. Artisan Partners Limited Partnership lifted its stake in Twist Bioscience by 26.7% during the third quarter. Artisan Partners Limited Partnership now owns 6,410,900 shares of the company’s stock valued at $180,403,000 after purchasing an additional 1,349,867 shares during the last quarter. Millennium Management LLC boosted its holdings in Twist Bioscience by 151.5% during the third quarter. Millennium Management LLC now owns 1,793,850 shares of the company’s stock worth $50,479,000 after buying an additional 1,080,722 shares in the last quarter. Finally, ARK Investment Management LLC grew its position in Twist Bioscience by 12.4% in the fourth quarter. ARK Investment Management LLC now owns 7,559,495 shares of the company’s stock worth $239,787,000 after buying an additional 832,687 shares during the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.